BioSpace News Archive

BIONIK Laboratories Corp. (OTCQB:BNKL) (“BIONIK”), today announced it has selected Propel, the product success platform built on Salesforce, to be its Product Lifecycle Management and Quality Management System solutions provider to accelerate new product development and manufacturing of InMotion™ products and services.

Project 10K is a clinical study to find novel diagnostic, prognostic, and therapeutic biomarkers for diseases based on applying state of the art machine learning methods to deep phenotypic and multi-omics measurements of 10,000 human volunteers over a 10-year period.

Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced a poster presentation of its lead cognitive disorder asset CAD-9303, a positive allosteric a novel, first-in-class, positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors.

Report details global omega-3 demand by region and application; includes volume and value (2017-2021)

Kaiser Permanente is a nonprofit organization serving more than 12.2 million members and generating more than $82 billion in annual revenue.

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it is commencing an underwritten registered public offering of $200,000,000 of shares of its common stock.

Celmatix Inc., the leading precision health company advancing the fields of reproductive medicine and fertility at the intersection of big data and genomics, announced today that it has filed a legal complaint in the New York State Supreme Court for New York County against 23andMe, Inc., a research partner of the Company

Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced positive topline results from the in-clinic stage of a Phase 2 study of its developmental ready-to-use (RTU) glucagon in patients who experience postprandial hypoglycemic episodes following bariatric surgery.

SYNIMMUNE GmbH, a biotechnology company focusing on the development of innovative and effective anti-tumor antibodies for orphan hematopoietic malignancies, announced today that interim results of its first-in-human clinical study of FLYSYN, a novel Fc-optimized antibody, for the treatment of acute myeloid leukemia (AML) were presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.

Dr. Dervieux joins Prometheus Biosciences from Exagen Diagnostics, a diagnostic company focused on chronic autoimmune diseases, where he served as chief scientific officer and medical director.